Mucopolysaccharidosis-II (MPS-II) Hunter Syndrome - Forecast in 26 Major Markets 2017-2027 - Variation by Geography & Ethnicity

Dublin, Feb. 09, 2017 -- Research and Markets has announced the addition of the "Mucopolysaccharidosis-II (MPS-II) Hunter Syndrome Forecast in 26 Major Markets 2017-2027" report to their offering.

Mucopolysaccharidosis-II, also known as MPS-II or Hunter syndrome, is part of the Mucopolysaccharidoses (MPS) disorders - a group of rare genetic disorders caused by deficiencies of lysosomal enzymes. MPS II is caused by deficiency of the lysosomal enzyme iduronate-2-sulphatase (IDS gene) leading to progressive accumulation of glycosaminoglycans in nearly all cell types, tissues and organs. It is a progressively debilitating disorder; however, the rate of progression varies among affected individuals.

Unlike other MPS disorders, MPS-II nearly exclusively affects males since it is an X-linked disorder. Few cases of females have been noted; however these cases tend to milder and very rare. MPS-II is typically classified as Severe (with neurological / cognitive impairment) or attenuated / mild (without neurological / cognitive impairment).

This report provides the current prevalent population for MPS-II across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Ireland, Brazil, Mexico, Japan, South Korea, China, India, Australia, Netherlands, Denmark, Sweden, Norway, Turkey, Portugal, Bulgaria, Poland, Estonia, Russia and Czech Republic) split by 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Main symptoms and co-morbidities for MPS-II include:

• Severe airway obstruction
• Skeletal deformities
• Cardiomyopathy
• Neurological decline
• Hearing loss and otitis

Reasons to Buy:

• Able to quantify patient populations in global MPS-II market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of MPS-II and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on MPS-II prevalent population.
• Identify sub-populations within MPS-II which require treatment.
• Gain an understanding of the specific markets that have the largest number of MPS-II patients.

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key comorbid conditions/Features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line prevalence for MPS-II

10. Features of MPS-II patients

11. Abbreviations used in the report

12. Patient-Based Offering

13. Online Pricing Data and Platforms

14. References

15. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/4nvk5f/mucopolysaccharido

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Endocrine and Metabolic Disorders Drugs